Vigonvita Life Sciences Co., Ltd. will convene its 2026 annual general meeting (AGM) at 10:00 a.m. on 26 June 2026 at the group’s Suzhou headquarters (8th Floor, Building A, No. 108 Yuxin Road, Suzhou Industrial Park). Shareholders—both H-share and unlisted—are invited to vote on 14 resolutions covering performance review, profit allocation, board re-election and capital authorisations.
Key items on the agenda are as follows:
1. Operating and Financial Review • Approval of the 2025 annual report, Board work report and final accounts. • Endorsement of the 2025 profit-distribution plan. • Review of the 2025 report from independent non-executive directors and confirmation of the 2026 remuneration package for all directors.
2. Corporate Governance Changes • Election of a new nine-member board: three executive/non-executive directors (Dr Tian Guanghui, Dr Hu Tianwen, Mr Liu Haoxuan) and three independent non-executive directors (Dr Ju Dianwen, Ms Cao Xinwen, Dr Xu Hongxi) will be chosen via cumulative voting. • Special resolution to abolish the Supervisory Committee and make corresponding amendments to the Articles of Association, signalling a shift toward a board-centric governance structure. • Amendments to the Rules of Procedure for Shareholders’ Meetings and Board Meetings.
3. Capital and Risk Management • Request for shareholder approval of a general mandate to issue additional H-shares and a separate mandate to repurchase H-shares, enhancing financial flexibility. • Authorisation for the provision of guarantees to subsidiaries, aimed at supporting group-wide operational and financing activities. • Engagement of HLB Hodgson Impey Cheng Limited as external auditor for the next fiscal year, with remuneration to be set by the Board.
Shareholders may appoint the AGM chairman or another chosen proxy to vote on their behalf. Proxy forms must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 25 June 2026. Completion and return of the form will not preclude shareholders from attending and voting in person.
The meeting’s outcomes will influence Vigonvita’s governance framework, capital policy and leadership composition ahead of its second board term, making participation critical for both H-share and domestic shareholders.